中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (8): 2319-2320.doi: 10.4103/NRR.NRR-D-24-00489

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

卡铂可恢复 FUS 相关肌萎缩侧索硬化症的神经元毒性

  

  • 出版日期:2025-08-15 发布日期:2024-12-13

Carboplatin restores neuronal toxicity in FUS-linked amyotrophic lateral sclerosis

Kiyoung Kim*   

  1. Department of Medical Science, Soonchunhyang University, Asan, Korea
  • Online:2025-08-15 Published:2024-12-13
  • Contact: Kiyoung Kim, PhD, kiyoung2@sch.ac.kr.
  • Supported by:
    This work was supported by the BK21 FOUR (Fostering Outstanding Universities for Research), the Basic Science Research Program through the National Research Foundation of Korea (NRF), and the Regional Innovation Mega Project Program through the Korea Innovation Foundation funded by the Ministry of Education (MOE) and the Ministry of Science and ICT (MSIT) (NRF-2022R1A2C1004204, RS-2023-00219563, 2023-DD-UP-0007) and by the Soonchunhyang University Research Fund (to KK).

摘要: https://orcid.org/0000-0002-4879-5207 (Kiyoung Kim)

Abstract: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig ’s disease, is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord. This leads to muscle weakness, paralysis, and ultimately, respiratory failure (Cha and Kim, 2022). There is currently no cure for ALS. Riluzole, a primary treatment for ALS, has been shown to extend survival by an average of three months. Another drug, Edaravone, has been approved for ALS treatment in some countries; however, its efficacy remains controversial (Cha and Kim, 2022). These drugs target various mechanisms that contribute to neuronal degeneration in ALS, including glutamate excitotoxicity and oxidative stress. Although several studies have attempted to elucidate the underlying mechanisms, there remains an unmet need for more effective therapies to halt or reverse disease progression. Therefore, novel therapeutic strategies are urgently needed.